Mary E Klein
Overview
Explore the profile of Mary E Klein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
334
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Klein M, Dickson M, Antonescu C, Qin L, Dooley S, Barlas A, et al.
Oncogene
. 2018 May;
37(37):5066-5078.
PMID: 29789718
CDK4/6 inhibitors are being used to treat a variety of human malignancies. In well-differentiated and dedifferentiated liposarcoma their clinical promise is associated with their ability to downregulate the MDM2 protein....
2.
Klein M, Kovatcheva M, Davis L, Tap W, Koff A
Cancer Cell
. 2018 May;
34(1):9-20.
PMID: 29731395
CDK4/6 inhibitors are among a new generation of therapeutics. Building upon the striking success of the combination of CDK4/6 inhibitors and the hormone receptor antagonist letrozole in breast cancer, many...
3.
Kovatcheva M, Klein M, Tap W, Koff A
Mol Cell Oncol
. 2018 Feb;
5(1):e1384882.
PMID: 29404388
Senescence is an irreversible form of growth arrest and is generally considered a favorable outcome of cancer therapies, yet little is known about the molecular events that distinguish this state...
4.
Kovatcheva M, Liao W, Klein M, Robine N, Geiger H, Crago A, et al.
Nat Commun
. 2017 Sep;
8(1):386.
PMID: 28855512
Senescence is a state of stable cell cycle exit with important implications for development and disease. Here, we demonstrate that the chromatin remodeling enzyme ATRX is required for therapy-induced senescence....
5.
Kovatcheva M, Liu D, Dickson M, Klein M, OConnor R, Wilder F, et al.
Oncotarget
. 2015 Mar;
6(10):8226-43.
PMID: 25803170
CDK4 inhibitors (CDK4i) earned Breakthrough Therapy Designation from the FDA last year and are entering phase III clinical trials in several cancers. However, not all tumors respond favorably to these...
6.
Tula-Sanchez A, Havas A, Alonge P, Klein M, Doctor S, Pinkston W, et al.
Cancer Biol Ther
. 2013 Aug;
14(10):949-61.
PMID: 23982416
Diffuse large B cell lymphoma (DLBCL) is an aggressive form of non-Hodgkin lymphoma. While the initial treatment strategy is highly effective, relapse occurs in 40% of cases. Histone deacetylase inhibitors...